Histologic Ex Vivo Validation of the [<sup>18</sup>F]SITATE Somatostatin Receptor PET Tracer

Radiolabeled somatostatin analogs (SSAs), such as [<sup>68</sup>Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [<sup>18</sup>F]SITATE presents a promising alternative, offering the advantage of a longer half-life than <sup>68</sup>Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [<sup>18</sup>F]SITATE. <b>Methods:</b> This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [<sup>18</sup>F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUV<sub>mean</sub>, SUV<sub>peak</sub>, SUV<sub>max</sub>, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1-3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology. <b>Results:</b> PET imaging demonstrated a significant correlation between [<sup>18</sup>F]SITATE uptake (SUV<sub>mean</sub> and TLR) and SSTR type 2 H-scores (<i>r</i> = 0.618 and 0.622, respectively; <i>P</i> < 0.0001). SSTR score 3 correlated with increased SUV<sub>mean</sub> and TLR (<i>P</i> < 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. <b>Conclusion:</b> [<sup>18</sup>F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This <sup>18</sup>F-labeled tracer shows specificity comparable to historical [<sup>68</sup>Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [<sup>18</sup>F]SITATE with traditional [<sup>68</sup>Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine
Published
2025-05-22
DOI
https://doi.org/10.2967/jnumed.125.269619
Citations
1
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
1.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer

Gerald Reischl, Sven Mattern, Konstantin Nikolaou, Christian la Fougère et al.
1 citations
Journal of Nuclear Medicine
Neuroendocrine Tumor Research Advances
1.35
article

Histologic Ex Vivo Validation of the [18F]SITATE Somatostatin Receptor PET Tracer

Gerald Reischl, Sven Mattern, Konstantin Nikolaou, Christian la Fougère, Silvio Nadalin, Nils Florian Trautwein, Ralf Schirrmacher, Volker Steger, Johannes Schwenck, Martina Hinterleitner, Stephan Singer
article en
1 citations

Abstract

Radiolabeled somatostatin analogs (SSAs), such as [<sup>68</sup>Ga]Ga-DOTA SSAs, have transformed imaging and therapeutic strategies. However, their use is constrained by the high cost of generators and their short half-life. In contrast, [<sup>18</sup>F]SITATE presents a promising alternative, offering the advantage of a longer half-life than <sup>68</sup>Ga, along with the cost-effectiveness of cyclotron-based production. This study evaluated the first histologic ex vivo validation of [<sup>18</sup>F]SITATE. <b>Methods:</b> This study retrospectively included 47 patients (57% male; mean age, 66.9 ± 14.9 y) with histologically confirmed well-differentiated neuroendocrine neoplasms who underwent [<sup>18</sup>F]SITATE PET followed by surgery within 4 mo. Lesion uptake was quantified using SUV<sub>mean</sub>, SUV<sub>peak</sub>, SUV<sub>max</sub>, and tumor-to-liver ratio (TLR). Histologic somatostatin receptor (SSTR) type 2 expression was determined using histological scores (H-scores), with thresholds defining SSTR scores 1-3. The accuracy of PET imaging for preoperative metastatic detection was evaluated against surgical histology. <b>Results:</b> PET imaging demonstrated a significant correlation between [<sup>18</sup>F]SITATE uptake (SUV<sub>mean</sub> and TLR) and SSTR type 2 H-scores (<i>r</i> = 0.618 and 0.622, respectively; <i>P</i> < 0.0001). SSTR score 3 correlated with increased SUV<sub>mean</sub> and TLR (<i>P</i> < 0.0001). Among 35 patients with primary resection and lymphadenectomy, PET achieved a sensitivity of 73.9% and specificity of 100%. <b>Conclusion:</b> [<sup>18</sup>F]SITATE PET imaging strongly correlates with histologic SSTR expression, demonstrating utility in staging and guiding therapeutic decisions in neuroendocrine neoplasms. This <sup>18</sup>F-labeled tracer shows specificity comparable to historical [<sup>68</sup>Ga]Ga-DOTA SSA data, whereas an increase in sensitivity for the detection of locoregional metastases appears possible. Further head-to-head comparisons of [<sup>18</sup>F]SITATE with traditional [<sup>68</sup>Ga]Ga-DOTA SSA and histologic validation are warranted to optimize its diagnostic accuracy and clinical impact.

Journal of Nuclear MedicineVol. 66(8)
Siemens (Germany) (DE), University of Alberta (CA), German Cancer Research Center (DE), European Neuroendocrine Tumor Society (DE), STZ eyetrial (DE), University of Tübingen (DE)
Zero hunger
Openalex Percentile: Top 20%
Neuroendocrine Tumor Research Advances
1.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.